ADULT-ONSET STILL'S DISEASE: A FORGOTTEN MYTH
Article Sidebar
Main Article Content
Abstract
Adult-onset Still’s disease (AOSD), also known as Wissler-Fanconi syndrome is a rare systemic disorder. Symptoms usually include fever, joint pain, and rash. The diagnosis of ASOD is mostly clinical and excludes other possible causes. In this case report, a 25 years old gentleman, who in the recent past was diagnosed and treated with septic and reactive arthritis. He presented to us with a salmon-colored rash along with arthritis and was diagnosed as AOSD on the basis of clinical criteria, leukocytosis, raised inflammatory markers i.e., serum ferritin after the exclusion of other conditions.
Article Details
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
Still GF. On a form of chronic joint disease in children. Med Chir Trans. 1897;80:47-60.9.
Owlia MB, Mehrpoor G. Adult-onset Stills disease: A review. Indian J Med Sci. 2009; 63(5):207-21.
Kadavath S, Efthimiou P. Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med. 2015;47(1):6–14. DOI.org/10.3109/07853890.2014.971052
Kim H-A, Han JH, Kim W-J, Noh HJ, An J-M, Yim H, et al. TLR4 endogenous ligand S100A8/A9 levels in adult-onset Still’s a disease and their association with disease activity and clinical manifestations. Int J Mol Sci. 2016;17(8):1342. DOI.org/10.3390/ijms17081342
Wang Z, Chi H, Sun Y, Teng J, Feng T, Liu H, et al. Serum sTREM-1 in adult-onset Still’s a disease: a novel biomarker of disease activity and a potential predictor of the chronic course. Rheumatology (Oxford). 2020;59(11):3293–302. DOI.org/10.1093/rheumatology/keaa135
Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14(10):603–18.DOI.org/10.1038/s41584-018-0081-x
Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for the classification of adult Still’s disease. J Rheumatol. 1992;19(3):424–30.
Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, Castañeda S, Olivé A, Riveros A, et al. Efficacy of anakinra in refractory adult-onset Still’s disease: Multicenter study of 41 patients and literature review. Medicine (Baltimore) . 2015;94(39):e1554. DOI.org/10.1097/MD.0000000000001554
Sfriso P, Bindoli S, Doria A, Feist E, Galozzi P. Canakinumab for the treatment of adult-onset Still’s disease. Expert Rev Clin Immunol. 2020;16(2):129–38. DOI.org/10.1080/1744666X.2019.1707664
Ruscitti P, Rago C, Breda L, Cipriani P, Liakouli V, Berardicurti O, et al. Macrophage activation syndrome in Still’s disease: analysis of clinical characteristics and survival in paediatric and adult patients. Clin Rheumatol . 2017;36(12):2839–45. DOI.org/10.1007/s10067-017-3830-3